Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
The Ras Gene02:38

The Ras Gene

6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The spontaneous neoantigen-specific CD4<sup>+</sup> T-cell response to a growing tumor is functionally and phenotypically diverse.

Journal for immunotherapy of cancer·2025
Same author

Detailed analysis of the effects of a NOT gate on activation and growth of T cells.

Cytotherapy·2025
Same author

Normal Treg homeostasis and suppressive function require both FOXP1 and FOXP4.

JCI insight·2025
Same author

The spontaneous neoantigen-specific CD4<sup>+</sup> T cell response to a growing tumor is functionally and phenotypically diverse.

bioRxiv : the preprint server for biology·2025
Same author

Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy.

Frontiers in immunology·2025
Same author

Editorial: The next stage of immune cell design: selective targeting of multi-antigen profiles.

Frontiers in immunology·2025

Related Experiment Video

Updated: Aug 8, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.8K

Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and

Talar Tokatlian1, Grace E Asuelime1, Martin S Naradikian1

  • 1Research, A2 Biotherapeutics, Agoura Hills, California.

Cancer Research Communications
|March 2, 2023
PubMed
Summary

Developing chimeric antigen receptor (CAR) T-cell therapies targeting KRAS mutations presents a potency-selectivity trade-off. Optimizing CARs for mutant KRAS requires careful balancing to avoid cross-reactivity with related proteins.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.5K

Related Experiment Videos

Last Updated: Aug 8, 2025

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.8K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.5K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Neoantigens are promising cancer-specific immuno-oncology targets.
  • Mutant KRAS proteins are attractive targets for off-the-shelf therapies.
  • Single amino acid differences in KRAS mutations pose molecular discrimination challenges.

Purpose of the Study:

  • To optimize single-chain variable fragments (scFvs) for chimeric antigen receptor (CAR) T-cell therapies targeting specific KRAS mutations (G12V, G12D).
  • To investigate the trade-off between potency and selectivity in KRAS pMHC-directed CARs.
  • To assess the risk of cross-reactivity with other G-protein family members.

Main Methods:

  • Optimization of scFvs against HLA-A*11/mutant KRAS peptide complexes.
  • Development and evaluation of CAR T-cell constructs.
  • Assessment of CAR T-cell potency and selectivity against various KRAS peptides and related proteins.

Main Results:

  • Optimized CARs demonstrated a trade-off between potency and selectivity.
  • High-potency CARs maintained selectivity against wild-type KRAS but lost selectivity against other KRAS-related peptides.
  • Targeting KRAS without high selectivity risks cross-reactivity with related G-proteins.

Conclusions:

  • Achieving both high potency and high selectivity in KRAS-targeted CAR T-cell therapy is challenging.
  • This study highlights the critical need to balance CAR T-cell efficacy and safety.
  • Further research is needed to overcome selectivity challenges for KRAS-targeted therapies.